Interactions on record — worth a quick check against your medications. Based on 2 of 3 ingredients. Check your meds →
Dietary supplement

Osteo Bi-Flex Ease Ingredients & Drug Interactions

by Osteo Bi-Flex

Tablet Or Pill Category: Other Combinations
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Osteo Bi-Flex Ease is a dietary supplement by Osteo Bi-Flex with 3 active ingredients. Its ingredients are commonly taken for bone health and osteoporosis, correcting vitamin d deficiency, immune system support.Based on those ingredients, 1,012 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Joint Shield 5-Loxin Advanced Boswellia serrata extract, Vitamin D. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Osteo Bi-Flex Ease by Osteo Bi-Flex

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 3 of its 3 active ingredients.
  • “UC-II standardized Cartilage” is listed as a grouped ingredient — the label gives one combined amount (40 mg) without saying how much of each component you get.

Osteo Bi-Flex Ease contains 3 active ingredients. Vitamin D supports bone health and calcium absorption—it's used for conditions like rickets, osteomalacia, and low parathyroid hormone (hypoparathyroidism).

Total Collagen and UC-II standardized Cartilage are connective tissue components meant to support joint structure. The product also contains several inactive ingredients including calcium carbonate, cellulose, stearic acid, and titanium dioxide as a color additive.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: support joint function and mobility.
  • We looked for evidence on: Knee pain, Osteoarthritis, Back pain, Exercise-induced muscle damage, Exercise-induced muscle soreness, Joint stiffness — and 3 related terms.
  • The strongest evidence on file: Boswellia Serrata is rated "Possibly Effective" for Osteoarthritis (Natural Medicines).
  • Also on file: Boswellia Serrata is rated "Insufficient Reliable Evidence To Rate" for Exercise-induced muscle soreness, Knee pain.
  • Also on file: Vitamin D is rated "Insufficient Reliable Evidence To Rate" for Back pain, Osteoarthritis, Exercise-induced muscle damage.

Vitamin D in this product is rated effective for rickets, osteomalacia (soft bones from vitamin D deficiency), renal bone disease, and low parathyroid hormone. For the Boswellia serrata extract, evidence shows it's possibly effective for osteoarthritis; the evidence for other uses like hay fever, asthma, and Alzheimer's disease is insufficient to rate.

We hold no effectiveness ratings for Total Collagen or UC-II standardized Cartilage.

The evidence, ingredient by ingredient Vitamin D Boswellia Serrata

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 2 of the 2 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 2 of 2.
  • General safety write-ups exist for 2 of 2.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Vitamin D is generally well tolerated at recommended doses, though very high doses over time can cause toxicity with symptoms like high blood calcium (hypercalcemia), weak bones in adults, or slowed growth in children. Vitamin D is likely safe during pregnancy and lactation at recommended amounts, though you should take it only under your doctor's guidance.

Boswellia serrata extract is generally well tolerated short-term, but quality and dose vary widely between products. It's best avoided during pregnancy and breastfeeding because there isn't enough safety data.

Common side effects from Boswellia include stomach pain, diarrhea, headache, heartburn, nausea, and itching; rarely, very large amounts can form a stomach blockage (bezoar).

Side effects, ingredient by ingredient Vitamin D Boswellia Serrata

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 2 of the 2 matched ingredients can interact with medications — Boswellia Serrata, Vitamin D.
  • The most serious interaction on file is rated Moderate.
  • Some involve high-stakes drug classes: immunosuppressants / transplant drugs; heart-rhythm medications.
  • For scale: 1,013 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking Osteo Bi-Flex Ease, check with your doctor or pharmacist if you take digoxin, any heart rhythm medication (like verapamil or diltiazem), thiazide water pills, atorvastatin, aluminum-containing products, calcipotriene cream, immunosuppressant drugs, or any medication processed through your liver—especially those handled by CYP2D6, CYP2C19, CYP1A2, CYP2C9, or CYP3A4 enzymes. No interactions are documented for the Total Collagen ingredient we could check.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

This product may help if you need vitamin D supplementation or are looking for joint support with Boswellia, especially for osteoarthritis. However, if you take digoxin, heart rhythm medications, cholesterol drugs, water pills, or drugs processed through your liver's CYP enzyme systems, you need to check your exact medications with your doctor or pharmacist before starting.

Talk it over with your own healthcare provider before adding this to your routine.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 2 of 3 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Jun 23, 2017.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Osteo Bi-Flex Ease, straight from the product label.

Brand Osteo Bi-Flex
Barcode (UPC) 030768646547
Net contents 70 Mini Tablet(s)
Market status On market
Date entered into DSLD Jun 23, 2017
DSLD ID 74460
Product type Other Combinations
Supplement form Tablet Or Pill
Dietary claims / uses Nutrient, All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years), Gluten Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Osteo Bi-Flex Ease by Osteo Bi-Flex, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Tablet(s)
Maximum serving Sizes:
1 Tablet(s)
UPC/BARCODE
030768646547
IngredientAmount% DV
Vitamin D10 mcg50%
Total Collagen10 mg--
UC-II standardized Cartilage40 mg--
Joint Shield 5-Loxin Advanced Boswellia serrata extract100 mg--

Other ingredients: Calcium Carbonate, Cellulose, Cellulose Coating, Stearic Acid, Croscarmellose, Polydextrose, Titanium Dioxide color, Contains <2% of

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Seals/Symbols

#1 Pharmacist recommended brand 2016-2017 U.S.News & World Report Pharmacy Times

Brand IP Statement(s)

Osteo Bi-Flex Joint Health

Enjoy a Range of Motion with Osteo Bi-Flex Ease! Say goodbye to traditional joint formulas and hello to Osteo Bi-Flex Ease.

Made to Move During the day, you move your joints in so many different ways, getting up, sitting down, bending and flexing.

Osteo Bi-Flex is America's #1 Joint Health brand and supports joint comfort, so you can enjoy a range of motion for your day's activities.

Start feeling the difference in your joints in just 7 days with the power of Joint Shield!

Osteo Bi-Flex is manufactured under the highest standards for product quality, purity and potency.

See bottom of box for more information about our Ambassador’s Club

2017

Compared to Osteo Bi-Flex One Per Day tablet.

Based on two human studies with 5-LOXIN ADVANCED where subjects rated their joint health over time, subjects’ joint health improved within 7 days, and continued to improve throughout the duration of the studies.

UC-II brand collagen complex with undenatured type II collagen (U.S. Patents 7,846,487, 7,083,820, 9,066,926 and EPO Patent EP1435906B1; Canadian Patent CA 2459981C; and Japanese Patent JP 4800574B2). UC-II is a registered trademark of InterHealth N.I. 5-Loxin ADVANCED is a trademark of PL Thomas - Laila Nutra, LLC. U.S. Patent #8,551,496 and patents pending.

Formula

UC-ll Collagen a unique natural source of collagen that supports joint comfort. Joint Shield 5-Loxin Advanced shows Improved Joint Comfort in 7 Days. Vitamin D3 an active & potent form of Vitamin D that helps support bone health.

UC-II collagen with joint shield

General Statements

Helps to: Support joint function Support joint mobility

#1 Pharmacist recommended brand

Joint health

80% smaller tablet

40 points Join the Ambassador’s Club for rewards Visit www.osteobiflex.com for more information.

Made in the USA with select ingredients from around the world.

Based on the results of the Pharmacy Times Survey among pharmacists who recommend a “bone/joint strengthener” dietary supplement, (2016-2017).

Based on Nielsen data for the 52 weeks ending June 25, 2016.

Precautions

Keep out of reach of children.

Tamper Resistant: Do not use if blister seal is cut, torn or open.

Caution: If you are pregnant, nursing, taking any medications or have any medical condition, consult your doctor before use.

Discontinue use and consult your doctor if any adverse reactions occur.

Not intended for use by persons under the age of 18.

As a reminder, discuss the supplements and medications you take with your health care providers.

Storage

Store at room temperature and avoid excessive heat.

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

General

64654 01B B55388

Suggested/Recommended/Usage/Directions

1 per day

Directions For Adult Use: Take one (1) tablet per day preferably with food.

FDA Statement of Identity

Dietary Supplement

Formulation

Free of gluten and shellfish Non-GMO

Advanced Triple Action

See for yourself

Osteo Bi-Flex Ease by Osteo Bi-Flex label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Osteo Bi-Flex Ease by Osteo Bi-Flex

These are the 3 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Tablet(s) Dosage formTablet Or Pill Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Vitamin D

Interacts with
715 drugs
10 mcg per serving Form: Cholecalciferol, Vitamin D3

Vitamin D is a fat-soluble vitamin that helps your body absorb calcium and is important for healthy bones, muscles, and immune function. Many people,...

Vitamin D monograph & interactions

UC-II standardized Cartilage

40 mg per serving
  • › Total Collagen
100 mg per serving

Boswellia serrata is a tree resin used in traditional medicine, mainly for joint pain and inflammation. Some studies suggest it may help with osteoart...

Joint Shield 5-Loxin Advanced Boswellia serrata extract monograph & interactions

Other (inactive) ingredients: Calcium Carbonate, Cellulose, Cellulose Coating, Stearic Acid, Croscarmellose, Polydextrose, Titanium Dioxide color, Contains <2% of. These complete the product’s ingredient list but are not active constituents.

Interaction report

Osteo Bi-Flex Ease by Osteo Bi-Flex Drug Interactions

Want to check YOUR meds against Osteo Bi-Flex Ease?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
1,012Drugs
1,012 Moderate

Ingredients driving the most interactions

Vitamin D 715

Each ingredient & the kinds of drugs it affects

For each ingredient in Osteo Bi-Flex Ease with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Joint Shield 5-Loxin Advanced Boswellia serrata extract6 drug types · 952 drugs

Cytochrome P450 1A2 (Cyp1A2) Substrates

Theoretically, Boswellia serrata might increase the levels of CYP1A2 substrates.
In vitro research shows that Boswellia serrata gum resin inhibits CYP1A2 enzymes.

Likelihood Possible Evidence D
Cytochrome P450 2C19 (Cyp2C19) Substrates

Theoretically, Boswellia serrata might increase the levels of CYP2C19 substrates.
In vitro research shows that Boswellia serrata gum resin inhibits CYP2C19 enzymes.

Likelihood Possible Evidence D
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, Boswellia serrata might increase the levels of CYP2C9 substrates.
In vitro research shows that Boswellia serrata gum resin inhibits CYP2C9 enzymes.

Likelihood Possible Evidence D
Cytochrome P450 2D6 (Cyp2D6) Substrates

Theoretically, Boswellia serrata might increase the levels of CYP2D6 substrates.
In vitro research shows that Boswellia serrata gum resin inhibits CYP2D6 enzymes.

Likelihood Possible Evidence D
Cytochrome P450 3A4 (Cyp3A4) Substrates

Theoretically, Boswellia serrata might increase or decrease the levels and clinical effects of CYP3A4 substrates.
In vitro research shows that Boswellia serrata gum resin inhibits CYP3A4 enzymes. Other in vitro research shows that Boswellia serrata extract inhibits CYP3A4 enzymes at most concentrations, although it may modestly induce enzyme activity at low concentrations.

Likelihood Possible Evidence D
Immunosuppressants

Theoretically, Boswellia serrata might alter the effects of immunosuppressive drugs.
Some in vitro research suggests that Boswellia serrata extracts might inhibit mediators of autoimmune disorders such as leukotrienes and reduce production of antibodies and cell-mediated immunity. However, other in vitro research suggests that, when coupled with calcium ions, boswellic acids containing the keto group have immunostimulant properties within specific cell signaling pathways.

Likelihood Possible Evidence D

Vitamin D8 drug types · 715 drugs

Aluminum

Vitamin D might increase aluminum absorption and toxicity, but this has only been reported in people with renal failure.
The protein that transports calcium across the intestinal wall can also bind and transport aluminum. This protein is stimulated by vitamin D, which may therefore increase aluminum absorption. This mechanism may contribute to increased aluminum levels and toxicity in people with renal failure, when they take vitamin D and aluminum-containing phosphate binders chronically.

Likelihood Probable Evidence B
Atorvastatin (Lipitor)

Vitamin D might reduce absorption of atorvastatin.
A small, low-quality clinical study shows that taking vitamin D reduces levels of atorvastatin and its active metabolites by up to 55%. However, while atorvastatin levels decreased, total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol levels did not substantially change. Atorvastatin is metabolized in the gut by CYP3A4 enzymes, and researchers theorized that vitamin D might induce CYP3A4, causing reduced levels of atorvastatin. However, this proposed mechanism was not specifically studied.

Likelihood Probable Evidence B
Calcipotriene (Dovonex)

Taking calcipotriene with vitamin D increases the risk for hypercalcemia.
Calcipotriene is a vitamin D analog used topically for psoriasis. It can be absorbed in sufficient amounts to cause systemic effects, including hypercalcemia. Theoretically, combining calcipotriene with vitamin D supplements might increase the risk of hypercalcemia.

Likelihood Probable Evidence D
Digoxin (Lanoxin)

Theoretically, hypercalcemia induced by high-dose vitamin D can increase the risk of arrhythmia from digoxin.
High doses of vitamin D can cause hypercalcemia. Hypercalcemia increases the risk of fatal cardiac arrhythmias with digoxin. Avoid vitamin D doses above the tolerable upper intake level (4000 IU daily for adults) and monitor serum calcium levels in people taking vitamin D and digoxin concurrently.

Likelihood Possible Evidence D
Diltiazem (Cardizem, Others)

Theoretically, hypercalcemia induced by high-dose vitamin D can reduce the therapeutic effects of diltiazem for arrhythmia.
High doses of vitamin D can cause hypercalcemia. Hypercalcemia can reduce the effectiveness of verapamil in atrial fibrillation. Theoretically this could also occur with diltiazem. Avoid vitamin D doses above the tolerable upper intake level (4000 IU daily for adults) and monitor serum calcium levels in people taking vitamin D and diltiazem concurrently.

Likelihood Probable Evidence B
Thiazide Diuretics

Theoretically, taking thiazide diuretics and high-dose vitamin D can increase the risk of hypercalcemia.
Thiazide diuretics decrease urinary calcium excretion, which could lead to hypercalcemia if vitamin D supplements are taken concurrently. This has been reported in people being treated with vitamin D for hypoparathyroidism, and also in elderly people with normal parathyroid function who were taking a thiazide, vitamin D, and calcium-containing antacids daily.

Likelihood Probable Evidence D
Verapamil (Calan, Others)

Hypercalcemia induced by high-dose vitamin D can reduce the therapeutic effects of verapamil for arrhythmia.
Hypercalcemia due to high doses of vitamin D can reduce the effectiveness of verapamil in atrial fibrillation. Avoid vitamin D doses above the tolerable upper intake level (4000 IU daily for adults) and monitor serum calcium levels in people taking vitamin D and verapamil concurrently.

Likelihood Probable Evidence B
Cytochrome P450 3A4 (Cyp3A4) Substrates

Vitamin D might induce CYP3A4 enzymes and reduce the bioavailability of CYP3A4 substrates.
There is some concern that vitamin D might induce CYP3A4. In vitro research suggests that vitamin D induces CYP3A4 transcription. Additionally, observational research has found that increased UV light exposure and serum vitamin D levels are associated with decreased serum levels of CYP3A4 substrates such as tacrolimus and sirolimus, while no association between UV light exposure or vitamin D levels and levels of mycophenolic acid, a non-CYP3A4 substrate, was found. A small, low-quality clinical study shows that taking vitamin D reduces levels of the CYP3A4 substrate atorvastatin and its active metabolites by up to 55%; however, the clinical effects of atorvastatin were not reduced. While researchers theorized that vitamin D might induce CYP3A4, this proposed mechanism was not specifically studied.

Likelihood Possible Evidence D
The maker

Brand information

Manufacturer and brand details for Osteo Bi-Flex Ease, from the product label.

Osteo Bi-Flex

See all Osteo Bi-Flex products
Name
Rexall Sundown, Inc.
City
Boca Raton
State
FL
ZipCode
33487
Phone Number
1-888-848-2435
Web Address
www.osteobiflex.com
Pharmacist Counseling Corner

Osteo Bi-Flex Ease by Osteo Bi-Flex: Common Questions

Does Osteo Bi-Flex Ease by Osteo Bi-Flex interact with any medications?
Yes. Based on its ingredients, Osteo Bi-Flex Ease has a known interaction with 1,012 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Osteo Bi-Flex Ease contains 3 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Is it safe to take during pregnancy?
Vitamin D is likely safe during pregnancy at recommended doses, but use it only under your doctor's guidance. Boswellia serrata extract is best avoided in pregnancy because there isn't enough safety data to know either way. Talk with your doctor about whether this product is right for you.
Is it safe while breastfeeding?
Vitamin D is likely safe while breastfeeding at recommended doses. Boswellia serrata safety is unknown during breastfeeding, so it's best to avoid it. Check with your doctor or pharmacist before taking this product if you're nursing.
What are the common side effects?
Boswellia serrata may cause stomach pain, diarrhea, headache, heartburn, nausea, and itching. Dizziness and vertigo have been reported in some studies. Vitamin D at recommended doses is generally well tolerated, but very high doses can cause toxicity.
Will this help my osteoarthritis?
The Boswellia serrata extract in this product is rated possibly effective for osteoarthritis. We don't have effectiveness data for the collagen or UC-II cartilage ingredients on file.
Does this product have fillers?
Yes—the product contains several inactive ingredients including cellulose, stearic acid, and other binders and coating agents to form the tablet.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Osteo Bi-Flex Ease is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Osteo Bi-Flex Ease label
Sources

Sources & How We Checked

Osteo Bi-Flex Ease's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 42 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Vitamin D 26 references
  1. McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
  2. Tatro DS, ed. Drug Interactions Facts. Facts and Comparisons Inc., St. Louis, MO. 1999.
  3. Koutkia P, Chen TC, Holick MF. Vitamin D intoxication associated with an over-the-counter supplement. N Engl J Med 2001;345:66-7. PubMed
  4. Bar-Or D, Yoel G. Calcium and calciferol antagonize effect of verapamil in atrial fibrillation. Br Med J 1981;282:1585-6.
  5. Demontis R, Leflon A, Fournier A, et al. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialyzed patients taking AI(OH)3. Clin Nephrol 1986;26:146-9.
  6. Crowe M, Wollner L, Griffiths RA. Hypercalcemia following vitamin D and thiazide therapy in the elderly. Practitioner 1984;228:312-3.
  7. Parfitt AM. Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism. Ann Intern Med 1972;77:557-63. PubMed
  8. Thiazide diuretics and the risk of osteoporosis. Pharmacist's Letter/Prescriber's Letter 2003;19(11):191105.
  9. Moon J. The role of vitamin D in toxic metal absorption. J Am Coll Nutr 1994;13:559-64.
  10. Demontis R, Reissi D, Noel C, et al. Indirect clinical evidence that 1alphaOH vitamin D<SUB>3</SUB> increases the intestinal absorption of aluminum. Clin Nephrol 1989;31:123-7.
  11. Adler AJ, Berlyne GM. Duodenal aluminum absorption in the rat: effect of vitamin D. Am J Physiol 1985;249:G209-13. PubMed
  12. Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: A new drug interaction with an unexpected consequence. Clin Pharmacol Ther 2009;85:198-203. PubMed
  13. Dietary reference intakes for calcium and vitamin D. Institute of Medicine, November 30, 2010. Available at: http://www.iom.edu/~/media/Files/Report%20Files/2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Vitamin%20D%20and%20Calcium%202010%20Repo
  14. Cox KA, Dunn MA. Aluminum toxicity alters the regulation of calbindin-D28k protein and mRNA expression in chick intestine. J Nutr 2001;131:2007-13. PubMed
  15. Escribano, J., Balaguer, A., Pagone, F., Feliu, A., and Roque, I. Figuls. Pharmacological interventions for preventing complications in idiopathic hypercalciuria. Cochrane.Database.Syst.Rev. 2009;(1):CD004754. PubMed
  16. Carlton, S., Clopton, D., and Cappuzzo, K. A. Vitamin D deficiency: appropriate replenishment therapies and the effects of vitamin D toxicity. Consult Pharm 2010;25(3):171-177. PubMed
  17. Wang, H., Xia, N., Yang, Y., and Peng, D. Q. Influence of vitamin D supplementation on plasma lipid profiles: a meta-analysis of randomized controlled trials. Lipids Health Dis. 2012;11:42. PubMed
  18. Turner AN, Carr Reese P, Fields KS, Anderson J, Ervin M, Davis JA, Fichorova RN, Roberts MW, Klebanoff MA, Jackson RD. A blinded, randomized controlled trial of high-dose vitamin D supplementation to reduce recurrence of bacterial vaginosis. Am J Obstet G PubMed
  19. Weiner M, Epstein FH. Signs and symptoms of electrolyte disorders. Yale J Biol Med. 1970;43(2):76-109.
  20. Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, Baggerly K, McDonnell SL. Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial. JAMA. 2017 Mar 28;317(12):1234-1243. PubMed
  21. Roth DE, Leung M, Mesfin E, Qamar H, Watterworth J, Papp E. Vitamin D supplementation during pregnancy: state of the evidence from a systematic review of randomised trials. BMJ. 2017;359:j5237. PubMed
  22. Murai IH, Fernandes AL, Sales LP, et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: A randomized clinical trial. JAMA. 2021.
  23. Wang Z, Schuetz EG, Xu Y, Thummel KE. Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol 2013;136:54-8. PubMed
  24. Doyle D, Browne U, Brickley A, Murphy D. Vitamin D-induced hypercalcaemia and acute kidney injury in sarcoidosis. BMJ Case Rep 2023;16(1):e250580. PubMed
  25. Williamson A, Martineau AR, Sheikh A, Jolliffe D, Griffiths CJ. Vitamin D for the management of asthma. Cochrane Database Syst Rev 2023;2(2):CD011511. PubMed
  26. Kinesya E, Santoso D, Gde Arya N, et al. Vitamin D as adjuvant therapy for diabetic foot ulcers: Systematic review and meta-analysis approach. Clin Nutr ESPEN 2023;54:137-143. PubMed

See these in context on the Vitamin D monograph →

Boswellia Serrata 16 references
  1. Gupta I, Gupta V, Parihar A, et al. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res 1998;3:511-4.
  2. Electronic Code of Federal Regulations. Title 21. Part 182 -- Substances Generally Recognized As Safe. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=182
  3. Kimmatkar N, Thawani V, Hingorani L, et al. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee--a randomized double blind placebo controlled trial. Phytomedicine 2003;10:3-7. PubMed
  4. Liu JJ, Nilsson A, Oredsson S, et al. Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis 2002;23:2087-93. PubMed
  5. Wildfeuer A, Neu IS, Safayhi H, et al. Effects of boswellic acids extracted from a herbal medicine on the biosynthesis of leukotrienes and the course of experimental autoimmune encephalomyelitis. Arzneimittelforschung 1998;48:668-74.
  6. Gupta I, Parihar A, Malhotra P, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001;67:391-5. PubMed
  7. Sengupta K, Alluri KV, Satish AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin. Arthritis Res Ther 2008;10:R85.
  8. Sengupta K, Krishnaraju AV, Vishal AA, et al. Comparative efficacy and tolerability of 5-Loxin and Aflapin against osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int J Med Sci 2010;7:366-77.
  9. Ernst E. Frankincense: systematic review. BMJ 2008;337:a2813. PubMed
  10. Kirste S, Treier M, Wehrle SJ, et al. Boswellia serratea extract acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial. Cancer 2011;117:3788-95.
  11. Frank A, Unger M. Analysis of frankincense from various Boswellia species with inhibitory activity on human drug metabolising cytochrome P450 enzymes using liquid chromatography mass spectrometry after automated on-line extraction. J Chromatogr A 2006;111 PubMed
  12. Altmann A, Poeckel D, Fischer L, et al. Coupling of boswellic acid-incuded Ca2+ mobilisation and MAPK activation to lipid metabolism and peroxide formation in human leucocytes. Br J Pharmacol 2004;141:223-32.
  13. El Fortia, M., Badi, H., Elalem, Kh, Kadiki, O., and Topov, Y. Olibanum bezoar: complication of a traditional popular medicine. East Mediterr.Health J 2006;12(6):927-929.
  14. Meshkat S, Mahmoodi Baram S, Rajaei S, et al. Boswellia serrata extract shows cognitive benefits in a double-blind, randomized, placebo-controlled pilot clinical trial in individuals who suffered traumatic brain injury. Brain Inj 2022;36(4):553-559. PubMed
  15. Haron MH, Dale O, Martin K, et al. Evaluation of the Herb-Drug Interaction Potential of Commonly Used Botanicals on the US Market with Regard to PXR- and AhR-Mediated Influences on CYP3A4 and CYP1A2. J Diet Suppl 2022. PubMed
  16. Valente IVB, Garcia D, Abbott A, et al. The anti-proliferative effects of a frankincense extract in a window of opportunity phase ia clinical trial for patients with breast cancer. Breast Cancer Res Treat 2024;204(3):521-530. PubMed

See these in context on the Boswellia Serrata monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring